Analysts See $0.22 EPS for National Research (NRCIA); Metlife (MET) Sentiment Is 0.89

January 15, 2018 - By Dolores Ford

MetLife, Inc., through its subsidiaries, provides life insurance, annuities, employee benefits, and asset management products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. The company has market cap of $56.12 billion. It operates in six divisions: U.S.; Asia; Latin America; Europe, the Middle East, and Africa; MetLife Holdings; and Brighthouse Financial. It currently has negative earnings. The firm offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, and critical illness insurance products; vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only and private floating rate funding agreements; and account guaranteed, separate account guaranteed, and trust guaranteed interest contracts.

Analysts expect National Research Corporation (NASDAQ:NRCIA) to report $0.22 EPS on February, 13.They anticipate $0.01 EPS change or 4.35% from last quarter’s $0.23 EPS. NRCIA’s profit would be $5.78M giving it 41.88 P/E if the $0.22 EPS is correct. After having $0.09 EPS previously, National Research Corporation’s analysts see 144.44% EPS growth. The stock increased 1.10% or $0.4 during the last trading session, reaching $36.85. About 15,683 shares traded. National Research Corporation (NASDAQ:NRCIA) has 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

National Research Corporation provides analytics and insights for the patient and employee experience in serving the healthcare providers, payers, and other healthcare organizations in the United States and Canada. The company has market cap of $967.85 million. The Company’s portfolio of subscription solutions offer information and analysis services in a range of elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. It has a 41.97 P/E ratio. The firm offers Market Insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate the needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools.

Investors sentiment decreased to 1.82 in Q3 2017. Its down 0.13, from 1.95 in 2017Q2. It is negative, as 5 investors sold National Research Corporation shares while 17 reduced holdings. 13 funds opened positions while 27 raised stakes. 6.04 million shares or 1.01% more from 5.98 million shares in 2017Q2 were reported. Envestnet Asset Management stated it has 2,295 shares. Hillsdale Invest Incorporated invested 0.21% in National Research Corporation (NASDAQ:NRCIA). Federated Pa stated it has 0% in National Research Corporation (NASDAQ:NRCIA). Tower Rech Limited Liability (Trc) holds 1,590 shares or 0% of its portfolio. Goldman Sachs Grp Incorporated has invested 0% in National Research Corporation (NASDAQ:NRCIA). Spark Ltd Liability invested in 8,500 shares. Rhumbline Advisers holds 0% or 10,617 shares. Royal Commercial Bank Of Canada invested in 0% or 5,174 shares. Bankshares Of Ny Mellon Corp owns 0% invested in National Research Corporation (NASDAQ:NRCIA) for 96,285 shares. Deutsche Bancorporation Ag owns 9,527 shares for 0% of their portfolio. Panagora Asset Mgmt accumulated 16,577 shares. Paradigm Asset Management Ltd Liability Corp reported 900 shares stake. Renaissance Tech Ltd Liability Corporation accumulated 228,000 shares or 0.01% of the stock. Bank Of America Corporation De holds 0% of its portfolio in National Research Corporation (NASDAQ:NRCIA) for 2,633 shares. First Quadrant Limited Partnership Ca reported 0.01% in National Research Corporation (NASDAQ:NRCIA).

The stock decreased 0.30% or $0.16 during the last trading session, reaching $53.33. About 5.48M shares traded or 27.99% up from the average. MetLife, Inc. (MET) has risen 13.92% since January 15, 2017 and is uptrending. It has underperformed by 2.78% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: